Effectiveness of ResArgin on Adult's Body Composition and Health
NCT ID: NCT06601049
Last Updated: 2024-09-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
NA
60 participants
INTERVENTIONAL
2024-08-15
2025-02-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Does ResArgin improve muscle loss? Does ResArgin improve sleep quality, activity, mood, and body satisfaction.
Researchers will compare ResArgin to a placebo (a look-alike substance that contains no active ingredients) to see if ResArgin works to improve muscle loss and related health outcomes.
Participants will:
Take ResArgin or the Placebo every day for 3 months
Assessment will occur at Baseline, Day 30, Day 60, and Day 90.
Participants will complete a daily diary of their mood and health.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluating the Clinical Efficacy of Resveratrol in Improving Metabolic and Skeletal Muscle Function in Patients With Heart Failure
NCT03525379
The Effects of Resveratrol Supplementation on Measurements of Health and Human Performance
NCT01244360
Strength Training and Resveratrol
NCT06585865
Effect of Acute Exercise on Exosome Associated Biomarkers
NCT05541133
Resveratrol Supplementation on Exercise in Healthy Sedentary Adults
NCT01615445
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Outcomes: Primary outcomes will be body composition. Secondary outcomes will be physical activity, food cravings, health-related quality of life, body satisfaction, basal metabolic rate, sleep behaviors, mood, anxiety, and perceived stress.
Study Design • Randomized double-blind placebo-controlled trial
o N = 60 men and women (30 adults in the ResArgin Condition and 30 adults in the Placebo Condition).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ResArgin
A resveratrol-based supplement. Participants will receive a daily oral dose of ResArgin containing \[50 mg/d\] of trans-Resveratrol for 90 days.
ResArgin
Resveratrol-based supplement
placebo
Placebo consists of oat hull. Participants receive a daily oral dose of a placebo matching the appearance and dosage form of ResArgin for 90 days.
ResArgin
Resveratrol-based supplement
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ResArgin
Resveratrol-based supplement
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* age range between 25 to 60 years
Exclusion Criteria
* history of seizures or epilepsy-related disorders
* musculoskeletal issues that would prohibit them from engaging in spontaneous activity,
* metabolic disorder
* sleep disorder
* psychiatric condition
* dietary aversions or restrictions including any animal sources of protein, dairy, fruits/vegetables, nut/seed allergy, eggs, and wheat/gluten or are currently following a carbohydrate restricted (under 20%) habitual diet.
* smokers
* consume excessive amounts of alcohol (\>3 drinks/d)
* actively intermittent fasting
* actively trying to lose weight or have lost more than ± 3kg in previous 3 months
* pregnant
* nursing
* trying to conceive
* changed their birth control in the past 3 months.
25 Years
60 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Dr. Heather Hausenblaus
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dr. Heather Hausenblaus
Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Jacksonville University
Jacksonville, Florida, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
WDL022024
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.